(Reuters) - GlaxoSmithKline ( GSK.L ) faces new allegations of corruption, this time in Syria , where the drugmaker and its distributor have been accused of paying bribes to secure business, according to a whistleblower's email reviewed by Reuters. Britain's biggest...
